Moderna and other groups get $60 million to develop Ebola vaccine

Global health organisation CEPI will give roughly $60 million to Moderna and to two other groups to accelerate the development of shots against Ebola Bundibugyo, the deadly virus that has swept through eastern Democratic Republic of Congo. The Coalition for Epidemic Preparedness Innovations was one of the early investors that helped to develop a vaccine at the height of the COVID-19 pandemic. Richard Hatchett, head of CEPI, told Reuters it was possible to get vaccines against Ebola Bundibugyo ready for trials within a couple of months. There are no approved vaccines or treatments for Ebola Bundibugyo. "Every day counts in the race against this deadly disease,” Hatchett said. He also said the promise of vaccines on "a not infinitely distant horizon" should help to start conversations about who would buy it and fund any roll-out. But he cautioned vaccine development can be unpredictable and the challenging security situation in eastern Congo would make trials complex. The outbreak has caused 282 confirmed cases, including 42 deaths, and around 1,100 suspected cases, according to the AfricaWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times